#United States #New York #Class Action #Securities Fraud #Vistagen

Class Action Lawsuit Filed Against Vistagen Therapeutics

A recent class action lawsuit has been initiated by Levi & Korsinsky, LLP against Vistagen Therapeutics, Inc. for securities fraud, impacting investors subsequently. This legal action primarily concerns the alleged misrepresentations made by the company regarding its phase 3 clinical trial results, thereby affecting the share prices throughout various timeframes. This article provides detailed insights into the lawsuit, the implications for investors, and important deadlines for participation.

Background on Vistagen Therapeutics

Vistagen Therapeutics, Inc. operates in the biotech industry, focusing on developing therapeutic solutions for various mood and anxiety disorders. The company’s investigational drug, fasedienol, aimed to address social anxiety disorder, showcased promising potential but recently faced turmoil following an unsuccessful clinical trial.

Allegations of Securities Fraud

The class action lawsuit points accused Vistagen of making misleading claims regarding the success of its clinical trial, known as PALISADE-3, that occurred between April 1, 2024, and December 16, 2025. According to the lawsuit, the company portrayed an overly optimistic view of the trial's results to investors while downplaying potentially detrimental information.

Details of the PALISADE-3 Trial and Subsequent Disclosures

On December 17, 2025, Vistagen disclosed that the Phase 3 study yielded no statistically significant improvements on the primary endpoint concerning social anxiety treatment. Notably, the announcement revealed that there was no difference in treatment efficacy between fasedienol and a placebo, causing stock prices to plummet from $4.36 a share to $0.86 within a day, reflecting a severe loss over 80% in value.

These developments led to heightened frustrations among investors, many of whom felt misled due to the positive outlook projected prior to the trial results' release.

Implications for Investors

Investors affected by these developments should take immediate action by considering participating in the lawsuit. The deadline to join the class action suit is March 16, 2026. Legal representation from Levi & Korsinsky signifies that those involved may seek compensation for their losses without upfront costs.

Next Steps for Interested Investors

To become part of the lawsuit, investors can contact Levi & Korsinsky through the provided email or phone number. Gaining insight into their share in any potential recovery is essential and does not obligate one to become a lead plaintiff—a significant advantage for investor participation.

Why Choose Levi & Korsinsky

With two decades of experience in securities litigation, Levi & Korsinsky emphasizes a proven track record of securing substantial recoveries for shareholders. Winning recognition in ISS Securities Class Action Services’ top rankings illustrates the firm’s effectiveness and commitment to representing investor rights.

Contact Details

For more information about the lawsuit and joining the class action, investors can reach out directly:

• - Joseph E. Levi, Esq.
• - Email: [email protected]
• - Phone: (212) 363-7500
• - Address: 33 Whitehall Street, 27th Floor, New York, NY 10004

In conclusion, Vistagen Therapeutics faces serious allegations that could reshape its trajectory while offering investors a chance to seek justice. With rising concerns around corporate transparency and accountability, this lawsuit serves as a crucial turning point for affected parties wishing to reclaim their investments.